Daily Stock Analysis, VBK, VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS., priceseries

VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.. Daily Stock Analysis
Stock Information
Open
236.76
Close
228.72
High
237.64
Low
228.43
Previous Close
236.41
Daily Price Gain
-7.69
YTD High
283.70
YTD High Date
Jan 4, 2022
YTD Low
222.50
YTD Low Date
Feb 24, 2022
YTD Price Change
-54.11
YTD Gain
-19.13%
52 Week High
306.37
52 Week High Date
Nov 8, 2021
52 Week Low
222.50
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-35.59
52 Week Gain
-13.47%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2019
149.93
Mar 4. 2019
174.96
39 Trading Days
16.69%
Link
LONG
Nov 19. 2020
240.74
Dec 29. 2020
264.09
26 Trading Days
9.70%
Link
Company Information
Stock Symbol
VBK
Exchange
TSE
Company URL
http://www.vbivaccines.com
Company Phone
6178303031
CEO
Jeff Baxter
Headquarters
Massachusetts
Business Address
222 THIRD STREET, SUITE 2241, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000704159
About

VBI Vaccines, Inc. is a biopharmaceutical company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology. Its products portfolio includes Sci-B-Vac, HBV, CMV Vaccine, GBM Immunotherapy and RSV Vaccine. The company is headquartered in Cambridge, MA.

Description

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.